A Phase III Clinical Trial Evaluating the Efficacy and Safety of Valsartan/Levamlodipine (SYH9056) Tablets In Hypertensive Patients

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

606

Participants

Timeline

Start Date

January 24, 2025

Primary Completion Date

March 30, 2026

Study Completion Date

October 30, 2026

Conditions

Mild-to-moderate Essential Hypertension

Interventions

DRUG

SYH9056

PO once daily, 1 tablet each time, each tablet contains 2.5mg levamlodipine and 80mg valsartan

DRUG

Levamlodipine

2.5mg PO once daily

DRUG

Valsartan

80mg PO once daily

DRUG

SYH9056 placebo

PO once daily

DRUG

Levamlodipine placebo

PO once daily

DRUG

valsartan placebo

PO once daily

All Listed Sponsors

lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY